Zirconium-based metal-organic framework UiO-66 was successfully prepared by solvothermal method,and UiO-66 was modified by adding regulators such as formic acid,acetic acid,and hydrochloric acid.The NH_(3)-SCR reactiv...Zirconium-based metal-organic framework UiO-66 was successfully prepared by solvothermal method,and UiO-66 was modified by adding regulators such as formic acid,acetic acid,and hydrochloric acid.The NH_(3)-SCR reactivity of the samples was evaluated by the denitration activity evaluation system,and the UiO-66 and the regulator-modified UiO-66 were characterized by XRD,SEM,BET,FTIR,TG,NH_(3)-TPD,etc.,the effects of regulator types on the structure and properties of UiO-66 were investigated.The experimental results show that,after adding the modifier,the morphology of UiO-66 changes from irregular quadrilateral with serious agglomeration to particles with regular crystal shape and good dispersibility,and the crystal morphology of the catalyst is improved.In addition,after adding the modifier,UiO-66 has a larger specific surface area and stronger surface acidity,which optimizes the catalytic performance of UiO-66.The catalytic performance test results of NH_(3)-SCR show that the low-temperature activity of UiO-66 is poor,and it only shows a certain catalytic activity at higher temperatures.The catalytic activity of UiO-66 was significantly improved after adding the regulator.Among them,the UiO-66-HCl modified with hydrochloric acid had the best catalytic activity,and the denitration rate reached 70%when the denitration temperature was 380℃.展开更多
目的探讨脑卒中后抑郁-焦虑共病(post-stroke anxiety combined with depression,PSCAD)患者合用安神合剂与黛力新治疗对其神经功能缺损、负性心理及不良反应的影响。方法选取2019年8月—2021年5月医院收治PSCAD患者146例,随机数字表法...目的探讨脑卒中后抑郁-焦虑共病(post-stroke anxiety combined with depression,PSCAD)患者合用安神合剂与黛力新治疗对其神经功能缺损、负性心理及不良反应的影响。方法选取2019年8月—2021年5月医院收治PSCAD患者146例,随机数字表法分对照组及观察组,各73例。对照组予以黛力新治疗,观察组在对照组基础之上联用安神合剂;比较治疗前与治疗4周后两组中医证候相关积分,酶联免疫分析仪检测血清5-羟色胺(5-hydroxytryptamine,5-HT)、盐酸多巴胺(Dopamine hydrochloride,DA)以及去甲肾上腺素(Norepinephrine,NE)水平,美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale,NIHSS)评估神经功能缺损现象,选取特质焦虑分量表(Trait anxiety invento⁃ry,T-AI)、状态焦虑分量表(S-AI)和汉密尔顿抑郁量表与(Hamilton Depression Scale,HAMD)进行负性心理评估;比较两组治疗后不良反应的发生率。结果治疗后,观察组中医症候相关积分皆明显优于对照组(P<0.05);治疗后,观察组血清5-HT、DA及NE水平显著高于对照组,观察组NIHSS评分明显低于对照组(P<0.05);治疗后,观察组T-AI、S-AI和HAMD评分皆明显低于对照组(P<0.05)。观察组不良反应发生率低于对照组,但差异不存在统计学意义(P>0.05)。结论安神合剂与黛力新联用改善PSCAD患者神经功能缺损状况,有效调节负性心理,不增加不良反应发生率。展开更多
基金Funded by the National Key Research and Development Program of China(No.2016YFC0209302)。
文摘Zirconium-based metal-organic framework UiO-66 was successfully prepared by solvothermal method,and UiO-66 was modified by adding regulators such as formic acid,acetic acid,and hydrochloric acid.The NH_(3)-SCR reactivity of the samples was evaluated by the denitration activity evaluation system,and the UiO-66 and the regulator-modified UiO-66 were characterized by XRD,SEM,BET,FTIR,TG,NH_(3)-TPD,etc.,the effects of regulator types on the structure and properties of UiO-66 were investigated.The experimental results show that,after adding the modifier,the morphology of UiO-66 changes from irregular quadrilateral with serious agglomeration to particles with regular crystal shape and good dispersibility,and the crystal morphology of the catalyst is improved.In addition,after adding the modifier,UiO-66 has a larger specific surface area and stronger surface acidity,which optimizes the catalytic performance of UiO-66.The catalytic performance test results of NH_(3)-SCR show that the low-temperature activity of UiO-66 is poor,and it only shows a certain catalytic activity at higher temperatures.The catalytic activity of UiO-66 was significantly improved after adding the regulator.Among them,the UiO-66-HCl modified with hydrochloric acid had the best catalytic activity,and the denitration rate reached 70%when the denitration temperature was 380℃.
文摘目的探讨脑卒中后抑郁-焦虑共病(post-stroke anxiety combined with depression,PSCAD)患者合用安神合剂与黛力新治疗对其神经功能缺损、负性心理及不良反应的影响。方法选取2019年8月—2021年5月医院收治PSCAD患者146例,随机数字表法分对照组及观察组,各73例。对照组予以黛力新治疗,观察组在对照组基础之上联用安神合剂;比较治疗前与治疗4周后两组中医证候相关积分,酶联免疫分析仪检测血清5-羟色胺(5-hydroxytryptamine,5-HT)、盐酸多巴胺(Dopamine hydrochloride,DA)以及去甲肾上腺素(Norepinephrine,NE)水平,美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale,NIHSS)评估神经功能缺损现象,选取特质焦虑分量表(Trait anxiety invento⁃ry,T-AI)、状态焦虑分量表(S-AI)和汉密尔顿抑郁量表与(Hamilton Depression Scale,HAMD)进行负性心理评估;比较两组治疗后不良反应的发生率。结果治疗后,观察组中医症候相关积分皆明显优于对照组(P<0.05);治疗后,观察组血清5-HT、DA及NE水平显著高于对照组,观察组NIHSS评分明显低于对照组(P<0.05);治疗后,观察组T-AI、S-AI和HAMD评分皆明显低于对照组(P<0.05)。观察组不良反应发生率低于对照组,但差异不存在统计学意义(P>0.05)。结论安神合剂与黛力新联用改善PSCAD患者神经功能缺损状况,有效调节负性心理,不增加不良反应发生率。
